Alexza Pharmaceuticals
Closed portfolio with an early-phase archive tilt
According to ClinicalTrials.gov-derived indexes, Alexza Pharmaceuticals sits in the top decile of US sponsors by registered trial count (#696 of 15,742 sponsors by registered trial count).
Alexza Pharmaceuticals: 22 sponsored US clinical trials, none currently recruiting.
Alexza Pharmaceuticals sponsors 22 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 21 completed. 3 of these trials are in Phase 3-4 (later-stage) and 19 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Thorough QT/QTc Study, with 1 trials.
Top-decile sponsor footprint
Alexza Pharmaceuticals ranks in the top decile of sponsors by registered trial count (#696 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
21 of 22 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (95.5%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Indexed trials (enrollment closed)
22 total, page 1 of 1
Study to Evaluate the Efficacy and Safety of Staccato Apomorphine (AZ-009) in Patients With Parkinson's Disease Experiencing OFF Episodes
NCT05979415
Staccato Granisetron® (AZ 010) for the Treatment of Cyclic Vomiting Syndrome
NCT04645953
Staccato® Granisetron Multiple Dose PK
NCT04327765
ADASUVE-Lorazepam Drug-Drug Interaction
NCT01877642
Staccato Loxapine Pulmonary Safety in Patients With COPD
NCT00889837
Staccato Loxapine Pulmonary Safety in Patients With Asthma
NCT00890175
Staccato Loxapine Thorough QT/QTc Study
NCT00874237
Staccato Loxapine PK in Smokers and Nonsmokers
NCT00873769
Staccato Loxapine in Migraine (Out Patient)
NCT00825500
Staccato Loxapine Pulmonary Safety in Healthy Volunteers
NCT00789360
Staccato Loxapine in Agitated Patients With Bipolar Disorder
NCT00721955
Staccato Loxapine in Agitated Patients With Schizophrenia
NCT00628589
Staccato Zaleplon Single Dose Pharmacokinetics
NCT00620620
Staccato Loxapine Multidose PK
NCT00555412
Staccato Prochlorperazine Thorough QT/QTc
NCT00543062
Staccato Loxapine in Migraine (in Clinic)
NCT00489476
Staccato Alprazolam in Panic Attack
NCT00477451
Staccato Loxapine in Agitation (Proof of Concept)
NCT00369577
Staccato Prochlorperazine in Migraine (Out Patient)
NCT00422812
Staccato Fentanyl Single and Multidose PK
NCT00402350
Staccato Loxapine Single Dose PK
NCT00444028
Staccato Prochlorperazine in Migraine (in Clinic)
NCT00610428
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 11 |
| Phase 2 | 8 |
| Phase 3 | 2 |
| Phase 4 | 1 |
Therapeutic Areas
How the Alexza Pharmaceuticals early-phase archive is shaped
22 indexed studies, none listed as recruiting (0% open); 21 completed (95%).
Phase mix: 3 late (III/IV) vs 19 early (I/II) (early-phase heavy).
Top condition: Thorough QT/QTc Study (1 trial), 1 other listed.
How to read a closed sponsor archive
When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.
Alexza Pharmaceuticals: archived-pipeline peers nationwide
Peers matched on 22 indexed studies with no current recruiting: volume and archive shape, not condition overlap.
Alexza Pharmaceuticals sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 22 archived trials
- Alaunos Therapeutics · 22 trials · 0% recruiting
- Calithera Biosciences · 22 trials · 0% recruiting
- Fate Therapeutics · 22 trials · 14% recruiting
- Griffin Hospital · 22 trials · 0% recruiting
Sponsors with similar archive density (± trial count)
- 10xBio · 0% recruiting · 3 trials
- 22nd Century Group · 0% recruiting · 3 trials
- 23andMe · 0% recruiting · 6 trials
- 3-C Institute for Social Development · 0% recruiting · 14 trials
Related
What to do with this Alexza Pharmaceuticals page
22 registered trials is a research-attention snapshot, not an endorsement of Alexza Pharmaceuticals or any single study.
- None of Alexza Pharmaceuticals's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- Thorough QT/QTc Study is the condition Alexza Pharmaceuticals studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Thorough QT/QTc Study trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Alexza Pharmaceuticals pipeline card: 22 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.